A cheer went up among Vizient and our members last year when HHS announced the termination of the FDA’s Unapproved Drugs Initiative to curb rising drug costs. Our analysis found that ending the program could protect the U.S. health care system from an additional $7.52 billion of cost. Read why Vizient is advocating for commonsense drug pricing solutions as the Biden Administration and federal regulatory agencies may soon take up the issue.
This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.